FDA: Evidentiary standards for drug development and approval

Overview of attention for article published in Neurotherapeutics, July 2004

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 2 news outlets

twitter: 11 X users

Citations

dimensions_citation: 86 Dimensions

Readers on

mendeley: 88 Mendeley
citeulike: 1 CiteULike

Summary News X Dimensions citations

So far, Altmetric has seen 2 news stories from 2 outlets.

Bringing Rigorous Testing to Health Care Policy

New York Times, 19 Mar 2021

Economic View Randomized, evidence-based trials, long required for new drugs, are now underway for government policy initiatives.

Pharmaceutical Executive Explains Decision to File Lawsuit Against FDA

Behavioral Healthcare, 24 Apr 2019

Ed Thompson, president of Pharmaceutical Manufacturing Research Services, made headlines in December when he filed a lawsuit…